MG
LRMR icon

Marex Group’s Larimar Therapeutics LRMR Stock Holding History

Marex Group’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-82,000
Closed -$369K – 1258
2026
Q1 		$369K Sell
82,000
-230,000
-74% -$919K ﹤0.01% 710
2025
Q4 		$1.19M Buy
312,000
+171,000
+121% +$665K 0.01% 383
2025
Q3 		$455K Buy
+141,000
New +$529K ﹤0.01% 515

Other funds holding LRMR

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

Marex Group's LRMR Position: Q2 2026 in Review

Marex Group sold out of Larimar Therapeutics (LRMR) in Q2 2026, closing a stake of 82,000 shares — an estimated $369K sold.

Marex Group first reported a position in LRMR in Q3 2025 and held it in 3 quarters. The position peaked at $1.19M in Q4 2025. 163 funds tracked by Wall St. Rank hold LRMR as of Q2 2026.

  • Marex Group reported no remaining Larimar Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Marex Group sold 82,000 Larimar Therapeutics shares in Q2 2026, an estimated $369K.
  • Marex Group first reported a position in Larimar Therapeutics in Q3 2025 and held it in 3 quarters.
  • Marex Group's Larimar Therapeutics position peaked at $1.19M in Q4 2025.
  • 163 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2026.

Based on Marex Group's 13F filing for Q2 2026, filed 14 Aug 2026.